Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.

Sthoeger Z, Sharabi A, Zinger H, Asher I, Mozes E.

Clin Immunol. 2018 Aug 28;197:34-39. doi: 10.1016/j.clim.2018.08.012. [Epub ahead of print]

PMID:
30170030
2.

Precision DNA demethylation ameliorates disease in lupus-prone mice.

Li H, Tsokos MG, Bickerton S, Sharabi A, Li Y, Moulton VR, Kong P, Fahmy TM, Tsokos GC.

JCI Insight. 2018 Aug 23;3(16). pii: 120880. doi: 10.1172/jci.insight.120880. [Epub ahead of print]

3.

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG.

Clin Cancer Res. 2018 Jun 13. doi: 10.1158/1078-0432.CCR-17-3427. [Epub ahead of print]

PMID:
29898992
4.

Heparanase is expressed in adult human osteoarthritic cartilage and drives catabolic responses in primary chondrocytes.

Gibor G, Ilan N, Journo S, Sharabi A, Dreyer J, Gertel S, Singh P, Menachem A, Snir N, Elkayam O, Vlodavsky I, Arad U.

Osteoarthritis Cartilage. 2018 Aug;26(8):1110-1117. doi: 10.1016/j.joca.2018.05.013. Epub 2018 May 24.

PMID:
29803826
5.

The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.

Sthoeger Z, Sharabi A, Asher I, Zinger H, Segal R, Shearer G, Elkayam O, Mozes E.

Clin Immunol. 2018 Jul;192:85-91. doi: 10.1016/j.clim.2018.05.001. Epub 2018 May 4.

PMID:
29730433
6.

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

PMID:
29472271
7.

Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans.

Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, Daly ME, Murphy JD.

Ann Thorac Surg. 2018 Feb;105(2):425-431. doi: 10.1016/j.athoracsur.2017.07.048. Epub 2017 Nov 30.

PMID:
29198624
8.

Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer.

Bryant AK, Mudgway R, Huynh-Le MP, Simpson DR, Mell LK, Gupta S, Sharabi AB, Murphy JD.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):478-485. doi: 10.1016/j.ijrobp.2017.09.034. Epub 2017 Sep 22.

PMID:
29102276
9.

Textual healing: tailor-made kabbalistic therapeutics in Jerusalem.

Guzmen-Carmeli S, Sharabi A.

Anthropol Med. 2017 Oct 30:1-15. doi: 10.1080/13648470.2017.1361653. [Epub ahead of print]

PMID:
29082780
10.

Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy.

Bryant AK, Huynh-Le MP, Simpson DR, Gupta S, Sharabi AB, Murphy JD.

JAMA Oncol. 2018 Jan 1;4(1):120-122. doi: 10.1001/jamaoncol.2017.2844. No abstract available.

PMID:
28975226
11.

The serine/threonine protein phosphatase 2A controls autoimmunity.

Sharabi A, Kasper IR, Tsokos GC.

Clin Immunol. 2018 Jan;186:38-42. doi: 10.1016/j.clim.2017.07.012. Epub 2017 Jul 21.

PMID:
28736280
12.

Immunotherapy and radiation in glioblastoma.

Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P.

J Neurooncol. 2017 Sep;134(3):531-539. doi: 10.1007/s11060-017-2413-0. Epub 2017 May 31. Review.

PMID:
28567588
13.
14.

Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System.

Anis S, Sharabi A, Mina Y, Klein A, Cagnano E, Elkayam O, Gurevich T.

Isr Med Assoc J. 2016 Oct;18(10):630-632. No abstract available.

15.

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R.

Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.

16.

Empowering Regulatory T Cells in Autoimmunity.

Kasper IR, Apostolidis SA, Sharabi A, Tsokos GC.

Trends Mol Med. 2016 Sep;22(9):784-797. doi: 10.1016/j.molmed.2016.07.003. Epub 2016 Jul 25. Review.

17.

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

Green G, Carmona R, Zakeri K, Lee CH, Borgan S, Marhoon Z, Sharabi A, Mell LK.

PLoS One. 2016 Jul 6;11(7):e0156489. doi: 10.1371/journal.pone.0156489. eCollection 2016. Review.

18.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

19.

Induced Sputum Analysis in Subjects With Systemic Sclerosis.

Litinsky I, Fireman E, Paran D, Polachek A, Broide A, Sharabi A, Anouk M, Elkayam O.

Respir Care. 2016 Oct;61(10):1369-73. doi: 10.4187/respcare.04706. Epub 2016 Jun 7.

20.

The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study.

Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O.

J Rheumatol. 2016 Sep;43(9):1749-54. doi: 10.3899/jrheum.151491. Epub 2016 Jun 1.

PMID:
27252430
21.

Editorial: Molecules Balancing Immunological Surveillance against Cancer and Autoimmune Diseases.

Sharabi A.

Front Oncol. 2016 Apr 12;6:86. doi: 10.3389/fonc.2016.00086. eCollection 2016. No abstract available.

22.

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

Sharabi AB, Lim M, DeWeese TL, Drake CG.

Lancet Oncol. 2015 Oct;16(13):e498-509. doi: 10.1016/S1470-2045(15)00007-8. Review.

PMID:
26433823
23.

A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients.

Robertson SP, Quon H, Kiess AP, Moore JA, Yang W, Cheng Z, Afonso S, Allen M, Richardson M, Choflet A, Sharabi A, McNutt TR.

Med Phys. 2015 Jul;42(7):4329-37. doi: 10.1118/1.4922686.

PMID:
26133630
24.

Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.

Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL.

Oncology (Williston Park). 2015 May;29(5):331-40. Review.

25.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.

Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG.

Cancer Immunol Res. 2015 Apr;3(4):345-55. doi: 10.1158/2326-6066.CIR-14-0196. Epub 2014 Dec 19.

26.

Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer.

Mdah W, Mzalbat R, Gilbey P, Stein M, Sharabi A, Zidan J.

Mol Clin Oncol. 2014 Nov;2(6):1107-1110. Epub 2014 Jul 11.

27.

Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.

Sthoeger Z, Sharabi A, Mozes E.

J Autoimmun. 2014 Nov;54:60-71. doi: 10.1016/j.jaut.2014.06.002. Epub 2014 Jun 21. Review.

PMID:
24958634
28.

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.

Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P.

J Immunother Cancer. 2014 May 14;2:14. doi: 10.1186/2051-1426-2-14. eCollection 2014. Review.

29.

Deep healing: ritual healing in the teshuvah movement.

Sharabi A.

Anthropol Med. 2014 Dec;21(3):277-289. Epub 2014 Apr 25.

PMID:
24766108
30.

Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.

Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM.

J Gastrointest Oncol. 2013 Dec;4(4):343-51. doi: 10.3978/j.issn.2078-6891.2013.044.

31.

The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.

Sthoeger Z, Zinger H, Sharabi A, Asher I, Mozes E.

PLoS One. 2013;8(3):e60394. doi: 10.1371/journal.pone.0060394. Epub 2013 Mar 28.

32.

Current standards and future directions for prostate cancer radiation therapy.

Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, Eble MJ.

Expert Rev Anticancer Ther. 2013 Jan;13(1):75-88. doi: 10.1586/era.12.156.

PMID:
23259429
33.

Holocaust survivors: three waves of resilience research.

Greene RR, Hantman S, Sharabi A, Cohen H.

J Evid Based Soc Work. 2012;9(5):481-97. doi: 10.1080/10911359.2011.566797.

PMID:
23092377
34.

Children's loneliness, sense of coherence, family climate, and hope: developmental risk and protective factors.

Sharabi A, Levi U, Margalit M.

J Psychol. 2012 Jan-Apr;146(1-2):61-83.

PMID:
22303613
35.

Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy.

Sharabi A, Haran-Ghera N.

Bone Marrow Res. 2011;2011:269519. doi: 10.1155/2011/269519. Epub 2011 Apr 6.

36.

Differences in pathological and clinical features of breast cancer in Arab as compared to Jewish women in Northern Israel.

Zidan J, Sikorsky N, Basher W, Sharabi A, Friedman E, Steiner M.

Int J Cancer. 2012 Aug 15;131(4):924-9. doi: 10.1002/ijc.26431. Epub 2011 Nov 17.

37.

Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations.

Telerman A, Lapter S, Sharabi A, Zinger H, Mozes E.

J Neuroimmunol. 2011 Mar;232(1-2):151-7. doi: 10.1016/j.jneuroim.2010.11.001. Epub 2010 Dec 3.

PMID:
21129786
38.

A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.

Lapter S, Ben-David H, Sharabi A, Zinger H, Telerman A, Gordin M, Leng L, Bucala R, Shachar I, Mozes E.

Immunology. 2011 Jan;132(1):87-95. doi: 10.1111/j.1365-2567.2010.03342.x. Epub 2010 Aug 25.

39.

Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model.

Sharabi A, Laronne-Bar-On A, Meshorer A, Haran-Ghera N.

Cancer Prev Res (Phila). 2010 Oct;3(10):1265-76. doi: 10.1158/1940-6207.CAPR-10-0138. Epub 2010 Aug 18.

40.

Bcl-xL affects the development of functional CD4 Tregs.

Sharabi A, Mozes E.

Arthritis Res Ther. 2010;12(4):405. doi: 10.1186/ar3076. Epub 2010 Jul 23. No abstract available.

41.

A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.

Mozes E, Sharabi A.

Autoimmun Rev. 2010 Nov;10(1):22-6. doi: 10.1016/j.autrev.2010.07.004. Epub 2010 Jul 23. Review.

PMID:
20659591
42.

Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy.

Sharabi A, Ghera NH.

Adv Cancer Res. 2010;107:1-37. doi: 10.1016/S0065-230X(10)07001-6. Review.

PMID:
20399959
43.
44.

In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+ CD25- cells in mice.

Arazi A, Sharabi A, Zinger H, Mozes E, Neumann AU.

PLoS One. 2009 Dec 24;4(12):e8447. doi: 10.1371/journal.pone.0008447.

45.

Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2.

Sharabi AB, Lee SH, Goodell MA, Huang XF, Chen SY.

Cloning Stem Cells. 2009 Dec;11(4):523-33. doi: 10.1089/clo.2009.0020.

46.

Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.

Lapter S, Marom A, Meshorer A, Elmann A, Sharabi A, Vadai E, Neufeld A, Sztainberg Y, Gil S, Getselter D, Chen A, Mozes E.

Arthritis Rheum. 2009 Dec;60(12):3744-54. doi: 10.1002/art.25013.

47.

A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.

Sharabi A, Dayan M, Zinger H, Mozes E.

J Clin Immunol. 2010 Jan;30(1):34-44. doi: 10.1007/s10875-009-9326-4. Epub 2009 Sep 16.

PMID:
19756988
48.

A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.

Ben-David H, Sharabi A, Parameswaran R, Zinger H, Mozes E.

Immunology. 2009 Oct;128(2):245-52. doi: 10.1111/j.1365-2567.2009.03109.x.

49.

A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice.

Sharabi A, Sthoeger ZM, Mahlab K, Lapter S, Zinger H, Mozes E.

Clin Immunol. 2009 Oct;133(1):61-8. doi: 10.1016/j.clim.2009.06.010. Epub 2009 Jul 23.

PMID:
19631585
50.

Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.

Sharabi A, Lapter S, Mozes E.

J Autoimmun. 2010 Mar;34(2):87-95. doi: 10.1016/j.jaut.2009.06.002. Epub 2009 Jul 12.

PMID:
19596183

Supplemental Content

Loading ...
Support Center